Vergent Bioscience

Vergent Bioscience, Inc. specializes in developing tumor-targeted fluorescent probes that enhance the surgical removal of cancerous tissue. Founded in 2013 and based in Minneapolis, Minnesota, the company’s flagship product, VGT-309, is a molecularly-targeted imaging molecule designed to bind to enzymes overexpressed in various tumor tissues. Upon injection before surgery, VGT-309 activates a brightly fluorescing dye, enabling surgeons to visually distinguish cancerous tissue from normal tissue during procedures. This technology aims to improve surgical outcomes by ensuring the complete removal of tumors, which is crucial for increasing cure rates. Vergent Bioscience's innovative approach addresses a significant clinical need for advanced visualization in various surgical settings, including open, laparoscopic, and robotic surgeries.